Alfasigma S.p.A.

23 clinical trials · Sponsor

Record	Firm	Date
Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents (NCT07554495)	Alfasigma S.p.A.	2026-05-21
OLE Study With Filgotinib in JIA (NCT07553182)	Alfasigma S.p.A.	2026-04-20
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis (NCT06865417)	Alfasigma S.p.A.	2025-09-29
Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA) (NCT06222034)	Alfasigma S.p.A.	2024-05-13
Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC) (NCT05817942)	Alfasigma S.p.A.	2023-06-12
A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis (NCT05785611)	Alfasigma S.p.A.	2023-04-05
Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France (NCT05323591)	Alfasigma S.p.A.	2022-05-03
Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). (NCT05724069)	Alfasigma S.p.A.	2021-12-15
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea (NCT05150587)	Alfasigma S.p.A.	2021-10-05
Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis (NCT04871919)	Alfasigma S.p.A.	2021-05-11
Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications. (NCT03469050)	Alfasigma S.p.A.	2018-07-02
Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test (NCT03864978)	Alfasigma S.p.A.	2018-06-22
A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention (NCT03537157)	Alfasigma S.p.A.	2017-11-16

Track Alfasigma S.p.A. automatically

Every clearance here is in the API, with alerts when new ones post.